Interestingly, GBM cells that were most sensitive to AURKA inhibition were those with high level of MYCN expression, although we must emphasize that the combined AURKA and BRD4 inhibition shows strong synergistic antitumor activity in all evaluated GBM cells, irrespective of MYCN levels (141). This evidence concerns the gene AURKA and glioblastoma.